Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of KBP-5074 in Moderate to Severe CKD With Uncontrolled Hypertension
CTR20221758Phase 3Terminated
- Sponsor
- Not applicable
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ocederenone in chronic kidney disease (CKD), hypertension (HTN), sponsored by Not applicable. Started Jul 2022; status: terminated.
02
Drugs
ocederenone
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on CTR20221758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221758.